Literature DB >> 12183277

Effect of lamivudine on transmission of human T-cell lymphotropic virus type 1 to adult peripheral blood mononuclear cells in vitro.

Emanuela Balestrieri1, Giancarlo Forte, Claudia Matteucci, Antonio Mastino, Beatrice Macchi.   

Abstract

The effects of lamivudine (3TC) on in vitro infection of peripheral blood mononuclear cells (PBMC) from healthy donors with human T-cell lymphotropic virus type 1 (HTLV-1) were investigated. Direct measures of viral replication (viral DNA, RNA, and protein) all gave similar, very high 50% inhibitory concentrations in comparison with those previously reported for zidovudine. Nevertheless, 3TC inhibited HTLV-1-driven long-term growth of infected PBMC in vitro at concentrations (6.25 micro M) which had poor or no direct antiviral effects, suggesting that another mechanism may be playing a role.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12183277      PMCID: PMC127437          DOI: 10.1128/AAC.46.9.3080-3083.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Efficacy of 3'-azido 3'deoxythymidine (AZT) in preventing HTLV-1 transmission to human cord blood mononuclear cells.

Authors:  J Zhang; E Balestrieri; S Grelli; C Matteucci; V Pagnini; C D'Agostini; A Mastino; B Macchi
Journal:  Virus Res       Date:  2001-10-30       Impact factor: 3.303

2.  In vivo fluctuation of HTLV-I and HTLV-II proviral load in patients receiving antiretroviral drugs.

Authors:  A Machuca; V Soriano
Journal:  J Acquir Immune Defic Syndr       Date:  2000-06-01       Impact factor: 3.731

3.  YADD mutants of human immunodeficiency virus type 1 and Moloney murine leukemia virus reverse transcriptase are resistant to lamivudine triphosphate (3TCTP) in vitro.

Authors:  P L Boyer; H Q Gao; P K Clark; S G Sarafianos; E Arnold; S H Hughes
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

4.  Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.

Authors:  J G García-Lerma; S Nidtha; W Heneine
Journal:  J Infect Dis       Date:  2001-07-25       Impact factor: 5.226

5.  Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells.

Authors:  I Miyoshi; I Kubonishi; S Yoshimoto; T Akagi; Y Ohtsuki; Y Shiraishi; K Nagata; Y Hinuma
Journal:  Nature       Date:  1981-12-24       Impact factor: 49.962

6.  Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy.

Authors:  G P Taylor; S E Hall; S Navarrete; C A Michie; R Davis; A D Witkover; M Rossor; M A Nowak; P Rudge; E Matutes; C R Bangham; J N Weber
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection.

Authors:  D Smith; M M Berrey; M Robertson; D Mehrotra; M Markowitz; L Perrin; N Clumeck; A Lazzarin; B Burckhardt; R Weber; L Corey; D A Cooper
Journal:  J Infect Dis       Date:  2000-08-17       Impact factor: 5.226

8.  Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase.

Authors:  J Y Feng; K S Anderson
Journal:  Biochemistry       Date:  1999-07-20       Impact factor: 3.162

Review 9.  Profound suppression of hepatitis B virus replication with lamivudine.

Authors:  C L Lai; M F Yuen
Journal:  J Med Virol       Date:  2000-07       Impact factor: 2.327

10.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

View more
  11 in total

1.  Lamivudine resistance in human T-cell leukemia virus type 1 may be due to a polymorphism at codon 118 (V-->I) of the reverse transcriptase.

Authors:  Carlos Toro; Berta Rodés; Carmen de Mendoza; Vincent Soriano
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

2.  Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon-α.

Authors:  Beatrice Macchi; Emanuela Balestrieri; Caterina Frezza; Sandro Grelli; Elena Valletta; Ambroise Marçais; Francesca Marino-Merlo; Jocelyn Turpin; Charles R Bangham; Olivier Hermine; Antonio Mastino; Ali Bazarbachi
Journal:  Blood Adv       Date:  2017-05-05

3.  Effect of phosphonated carbocyclic 2'-oxa-3'-aza-nucleoside on human T-cell leukemia virus type 1 infection in vitro.

Authors:  Emanuela Balestrieri; Claudia Matteucci; Arianna Ascolani; Anna Piperno; Roberto Romeo; Giovanni Romeo; Ugo Chiacchio; Antonio Mastino; Beatrice Macchi
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191

4.  Inhibitors of strand transfer that prevent integration and inhibit human T-cell leukemia virus type 1 early replication.

Authors:  Samira Rabaaoui; Fatima Zouhiri; Agnès Lançon; Hervé Leh; Jean d'Angelo; Eric Wattel
Journal:  Antimicrob Agents Chemother       Date:  2008-03-03       Impact factor: 5.191

Review 5.  Treatment of HTLV-I-associated myelopathy/tropical spastic paraparesis: toward rational targeted therapy.

Authors:  Unsong Oh; Steven Jacobson
Journal:  Neurol Clin       Date:  2008-08       Impact factor: 3.806

6.  Susceptibility of primary HTLV-1 isolates from patients with HTLV-1-associated myelopathy to reverse transcriptase inhibitors.

Authors:  Beatrice Macchi; Emanuela Balestrieri; Arianna Ascolani; Silva Hilburn; Fabiola Martin; Antonio Mastino; Graham P Taylor
Journal:  Viruses       Date:  2011-05-05       Impact factor: 5.048

7.  Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial.

Authors:  Graham P Taylor; Peter Goon; Yoshitaka Furukawa; Hannah Green; Anna Barfield; Angelina Mosley; Hirohisa Nose; Abdel Babiker; Peter Rudge; Koichiro Usuku; Mitsuhiro Osame; Charles R M Bangham; Jonathan N Weber
Journal:  Retrovirology       Date:  2006-09-19       Impact factor: 4.602

8.  How to Control HTLV-1-Associated Diseases: Preventing de Novo Cellular Infection Using Antiviral Therapy.

Authors:  Amandine Pasquier; Sandrine Alais; Loic Roux; Maria-Isabel Thoulouze; Karine Alvarez; Chloé Journo; Hélène Dutartre; Renaud Mahieux
Journal:  Front Microbiol       Date:  2018-03-13       Impact factor: 5.640

Review 9.  Antiretroviral Therapy in HTLV-1 Infection: An Updated Overview.

Authors:  Francesca Marino-Merlo; Emanuela Balestrieri; Claudia Matteucci; Antonio Mastino; Sandro Grelli; Beatrice Macchi
Journal:  Pathogens       Date:  2020-05-01

Review 10.  Future Perspectives on Drug Targeting in Adult T Cell Leukemia-Lymphoma.

Authors:  Francesca Marino-Merlo; Antonio Mastino; Sandro Grelli; Olivier Hermine; Ali Bazarbachi; Beatrice Macchi
Journal:  Front Microbiol       Date:  2018-05-09       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.